Cyclacel Pharmaceuticals, Inc.
CYCC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $9 | $8 | $1 | $782 |
| - Cash | $0 | $4 | $3 | $3 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $9 | $4 | -$3 | $779 |
| Revenue | $0 | $0 | $0 | -$0 |
| % Growth | – | – | 100% | – |
| Gross Profit | $0 | -$0 | $0 | -$0 |
| % Margin | 21% | – | – | 111.4% |
| EBITDA | -$0 | -$1 | -$5 | -$2 |
| % Margin | -1,208.6% | – | – | 5,385.7% |
| Net Income | -$0 | -$1 | -$0 | -$3 |
| % Margin | -1,219.8% | – | – | 8,720% |
| EPS Diluted | -1.31 | -0.84 | -6.25 | -0.35 |
| % Growth | -56% | 86.6% | -1,685.7% | – |
| Operating Cash Flow | $4 | -$0 | -$0 | -$1 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $4 | -$0 | -$0 | -$1 |